BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Core Insights - BridgeBio Pharma announced the presentation of cardiovascular outcomes data from its Phase 3 study of acoramidis in patients with ATTR-CM at the ACC Annual Scientific Sessions & Expo in March 2025 [1] Group 1: Presentation Details - Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy [2] - Acoramidis improves NYHA class at month 30 versus placebo in patients with ATTR-CM [2] - Addition of concomitant tafamidis did not further increase serum TTR levels in participants treated with acoramidis [3] - Efficacy results of acoramidis in ATTR-CM were robust according to pre-specified NT-proBNP sensitivity analyses [3] - Acoramidis-mediated early increase in serum transthyretin level reduces cardiovascular-related hospitalizations and mortality [3] Group 2: Moderated Posters - Primary endpoint efficacy results in the ATTRibute-CM study addressed tafamidis use [4] - Geographic healthcare disparities and diagnostic trends among patients with transthyretin amyloid cardiomyopathy [4] Group 3: Product Information - Attruby (acoramidis) is the first near-complete stabilizer of TTR approved in the U.S. for treating ATTR-CM in adults [5] - Attruby aims to reduce cardiovascular death and related hospitalizations and was generally well-tolerated with mild side effects [5] Group 4: Company Overview - BridgeBio Pharma focuses on discovering, creating, testing, and delivering transformative medicines for genetic diseases [6] - The company was founded in 2015 and has a pipeline ranging from early science to advanced clinical trials [6]